Quarterly Result12 Nov 2025, 05:12 pm
Supriya Lifescience Ltd. Approves Unaudited Financial Results for Q2 and H1 of FY2025-2026
AI Summary
Supriya Lifescience Ltd. has announced its unaudited financial results for the quarter and half year ended September 30, 2025. The company's revenue from operations stands at INR 1,998.33 million for Q2 and INR 3,449.07 million for H1. The total income for Q2 is INR 1,477.48 million and INR 3,503.06 million for H1. The company reported earnings per equity share of INR 6.27 for both basic and diluted for Q2 and H1. The cost of materials consumed is INR 437.76 million for Q2 and INR 1,173.08 million for H1. The company's total expenses for Q2 are INR 1,065.56 million and INR 2,096.32 million for H1.
Key Highlights
- Supriya Lifescience Ltd. announced unaudited financial results for Q2 and H1 of FY2025-2026.
- Revenue from operations stands at INR 1,998.33 million for Q2 and INR 3,449.07 million for H1.
- Total income for Q2 is INR 1,477.48 million and INR 3,503.06 million for H1.
- Earnings per equity share of INR 6.27 for both basic and diluted for Q2 and H1.
- Cost of materials consumed is INR 437.76 million for Q2 and INR 1,173.08 million for H1.
- Total expenses for Q2 are INR 1,065.56 million and INR 2,096.32 million for H1.